In a major milestone for science, for medicine, and for patients, the world’s first CRISPR drug has been approved in the UK. “A new treatment for sickle-cell disease and transfusion-dependent β-thalassemia has been authorised by the Medicines and Healthcare products Regulatory

HUGE week for CRISPR-based therapeutics 🥳

I 100% think it will. While we certainly have experts working on making this scientifically feasible (in vivo HSC editing is a doozy), there’s lots of people beyond science fighting to make life-saving medicines accessible globally. I have faith in them as well.

Our lab as well as students in the class I teach this semester enjoyed tasting the first CRISPR-edited salad greens, in which the myrosinase gene that results in the pungency of raw mustard greens (Brassica juncea) has been disabled, yielding a nutrient-dense, tasty, and

Congrats Sayo!

Happy Holidays from team Civilization VC! And welcome to our new Investment Partner, Samir Malhotra! Samir is a Stanford University grad, successful entrepreneur and former biopharma executive and consultant. Happy 2024 to all! Sonia Maryam Setayesh Kelcee Everette Ruxandra Teslo 🧬

Today we report in Nature Biotechnology an engineered virus-like particle system for in vivo delivery of prime editor protein-RNA complexes. This PE-eVLP platform can support therapeutic prime editing in animal models of genetic disease. /1 drive.google.com/file/d/1xd7Yzz…

Before day 1 of #JPM2024 officially ends, a B I G 💥🚀 Civilization VC announcement ... We have closed a fresh Civilization Opportunity Fund of $35M 💰🫰 with lots of dry powder ❄️ for both our scaling CV portfolio, and newcomers. ⛷️ Let's make 2024 the #Biotech Comeback

You asked for it, we brought it! 🙌 The Civilization VC Fellowship Class of 2024 is now recruiting ambitious #PhD #MD candidates who want to learn about #Entrepreneurship + #VentureCapital. Apply here: form.typeform.com/to/kPoMOa60 Past CV Fellows have gone on to found their own

Base and prime editors may offer more precision than #CRISPR #Cas9 for the future of genome editing. Read about the work by Gregory Newby Johns Hopkins Medicine and Kelcee Everette HMX on this technique to treat #sicklecelldisease. asbmb.org/asbmb-today/sc…

Today we report in Nature Communications the development of laboratory-evolved CBE6 cytosine base editors that offer high on-target C•G-to-T•A editing, virtually no A•T-to-G•C editing, low off-target editing, broad sequence context compatibility, and compatibility with multiple Cas

Today in @Science_Magazine we report the laboratory evolution of compact degrons that enable targeted protein degradation triggered by an otherwise-inert small molecule, a multidisciplinary study that integrates organic chemistry, molecular glues, protein evolution, genome

The defense and post-defense celebration of my dreams! Forever grateful to my village for supporting me through my PhD. No more “becoming”. I am officially Dr. Kelcee A. Everette! 🥳

Ten years and two degrees later, the honor, I assure you, was Harvard’s.

Today we report in Nature Biomedical Engineering the eePASSIGE system, which uses evolved and engineered recombinases and prime editing to integrate large gene-sized DNA cargoes into the mammalian genome in an efficient, precise, and targeted manner. (1/13) drive.google.com/file/d/1WDMVqL…

On #WorldSickleCellDay, we look to researchers, like Greg Newby (Johns Hopkins Medicine), Kelcee Everette (Broad Institute), & Benjamin L. Oakes (Scribe Therapeutics) who are developing the next generation of #SCD treatments with fewer side effects: asbmb.org/asbmb-today/sc….

Just started Supacell - immediately knew where it was going when Michael’s mom said he didn’t even have sickle trait (which would be impossible!)

Today we report in Nature Biomedical Engineering the systematic application of six recent prime editing developments to enable efficient and functional correction of CFTR F508del, the predominant mutation that causes cystic fibrosis (CF), in primary airway cells from CF patients.

Today we report in Nature Medicine the development of a base editing strategy for prion disease, currently a fatal and rapidly progressing neurogenerative condition with no effective treatment. @PrionAlliance DevermanLab (1/13) drive.google.com/file/d/1DVpKrz…

Congrats David R. Liu! What a wonderful and well-deserved award! 🎉